Teva has agreed to buy Labrys, a Californian manufacturer of pain products with a Phase IIb migraine product. The Israeli company said the acquisition adds an important dimension to its growing pain franchise.
Teva will pay up to $625m for Labrys dependent on milestones being met, with an upfront payment of $200m
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?